Navigation auf uzh.ch
Navigation auf uzh.ch
FimmCyte, founded in 2022 as a spin-off of UZH | USZ, announces a CHF 1 Million funding from the UZH Life Sciences Fund. FimmCyte's most advanced program is a non-hormonal disease-modifying treatment for endometriosis.
«We are thrilled to receive this investment from the UZH Life Science Fund, which recognizes the potential of our endometriosis treatment and the unmet medical need in women's health» said Mohaned Shilaih, CEO of FimmCyte. «This funding is a key steppingstone for FimmCyte as we fundraise for our Seed financing round with which we intend to advance our treatment into first in-human», Valentina Vongrad, CSO, added.
Valentina Vongard was awarded a UZH Entrepreneur Fellowship in 2022 to accompany and financially support her on her path to becoming an entrepreneur.
From Lab to Market: In the last year, eight new spin-offs were created at the UZH to bring research-based ideas to market readiness. Read the UZH Newsarticle
